Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies

OBJECTIVE: To assess the recurrence interval and predictive significance of TP53 expression and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastomas treated with radiotherapy and combined chemotherapies, including temozolomide, lomustine, procarbazine and bevacizumab....

Descripción completa

Detalles Bibliográficos
Autores principales: Kurdi, Maher, Butt, Nadeem Shafique, Baeesa, Saleh, Alghamdi, Badrah, Maghrabi, Yazid, Bardeesi, Anas, Saeedi, Rothaina, Dallol, Ashraf, Mohamed, Fawaz, Bari, Mohammed O., Samkari, Alaa, Lary, Ahmed I., Alkhayyat, Shadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084807/
https://www.ncbi.nlm.nih.gov/pubmed/33661424
http://dx.doi.org/10.1007/s11060-021-03723-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084807/
https://www.ncbi.nlm.nih.gov/pubmed/33661424
http://dx.doi.org/10.1007/s11060-021-03723-9

Ejemplares similares